What Is Teicoplanin Used For? Approved Uses, Per the Label

The short answer

Teicoplanin is a prescription glycopeptide antibiotic used in hospital and clinical settings where it is licensed. Its approved indications are set out in national prescribing information issued by the regulator of each country where the product is marketed, which includes European markets and Japan. In the United States, teicoplanin has no approved product label from the Food and Drug Administration, so there is no current US prescribing information whose indication wording could be quoted on this page. That regulatory fact, rather than any clinical judgement, is the reason the sections below describe published trial evidence instead of reproducing US label text.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any question regarding diagnosis, treatment or whether a specific antibiotic is appropriate.

What a label indication is, and why wording matters

An indication is a sentence in an approved prescribing information document stating the infection types and patient populations for which a regulator has accepted that a product's benefits were demonstrated. Indication wording is specific to the product, the regulator and the revision date of the document. Because label text differs between the European summaries of product characteristics, the Japanese package insert and other national documents, paraphrasing one of them as though it were universal would misrepresent the record. The verified sources used here are peer-reviewed trials, meta-analyses and guideline reviews, not regulatory documents, so this page names what those publications reported and does not reconstruct label sentences.

Regulatory status, stated positively

• Prescription status: teicoplanin is dispensed and administered under prescription and clinical supervision in the jurisdictions where it is licensed.
• Established clinical use in Japan: national professional bodies published a consensus review of therapeutic drug monitoring specifically for teicoplanin, issued jointly by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring (PMID 35022752), which reflects routine clinical use in that setting.
• United States: teicoplanin is absent from US treatment algorithms for this reason; a 2023 review of therapeutics for vancomycin-resistant enterococcal bloodstream infections discussed the glycopeptide class and its resistance landscape in detail (PMID 37067406).

None of the verified sources listed below report approval dates or regulatory decision histories, so no approval years, agency actions or supplement dates are stated on this page. Inventing them would be worse than omitting them.

Infection settings described in the published literature

Serious Gram-positive infection, compared with vancomycin

The most frequently cited comparative evidence for teicoplanin is a Cochrane meta-analysis of randomised trials in adults with proven or suspected Gram-positive infection. Researchers pooled trials comparing teicoplanin with vancomycin and reported similar clinical cure outcomes between the two glycopeptides alongside a lower frequency of adverse events with teicoplanin, including kidney-related events (PMID 26761092). That analysis is the backbone of most later discussions of where teicoplanin sits among glycopeptides.

MRSA infection

Methicillin-resistant Staphylococcus aureus is the organism most often studied with teicoplanin. A 2024 network meta-analysis compared six antibiotics used in MRSA infections, with teicoplanin among the agents assessed, and reported comparative effectiveness and safety estimates across the included trial network (PMID 38789000). A separate meta-analysis pooled randomised comparisons of linezolid against teicoplanin in MRSA infection and reported efficacy and safety comparisons between the two agents (PMID 31626598).

On the laboratory side, researchers characterised the pharmacodynamics of teicoplanin against MRSA and reported exposure-response relationships describing how drug exposure relative to the organism's minimum inhibitory concentration related to bacterial killing (PMID 28962026). That kind of work underpins the monitoring guidance described further below rather than defining any indication by itself.

Enterococcal infection and glycopeptide resistance

Enterococci complicate the glycopeptide picture because resistance determinants differ in whether teicoplanin activity is retained. A 2023 clinical microbiology review of therapeutics for vancomycin-resistant enterococcal bloodstream infections surveyed the available agents and discussed glycopeptide resistance phenotypes as part of treatment selection (PMID 37067406). Susceptibility testing of the specific isolate, not class membership, drives those decisions, and interpreting such results is a task for the treating clinician and the microbiology laboratory.

Class context: endocarditis and later-generation lipoglycopeptides

Teicoplanin belongs to a family that also includes newer long-acting lipoglycopeptides. A 2023 review examined dalbavancin as sequential therapy for infective endocarditis caused by Gram-positive organisms and summarised the published experience with that agent (PMID 36758775). That review concerns dalbavancin specifically; its conclusions were not reported for teicoplanin and are included here only as class context.

Therapeutic drug monitoring in the guideline literature

Where teicoplanin is licensed, measurement of blood concentrations is a recurring theme in the professional literature. The joint Japanese consensus review set out therapeutic drug monitoring practice for teicoplanin, covering which patients were considered for monitoring and how sampling was approached in clinical practice (PMID 35022752). A broader 2022 review on defining therapeutic ranges for antibiotic monitoring placed glycopeptides within the wider discussion of how target concentration ranges were derived and applied (PMID 34750338).

No target concentrations, infusion schedules, loading strategies or dose amounts are reproduced on this page. Those parameters are prescribing decisions made against an approved label, local protocols and individual patient factors, and they belong with a prescribing clinician and hospital pharmacy service.

Uses that are not approved indications: one factual note

Several publications describe teicoplanin outside licensed indications or outside clinical use altogether. These are not approved uses and are listed once, briefly, for completeness: a 2022 review surveyed published reports of subcutaneous administration of antibiotics, a route that is not an approved route of administration for the agents it covered (PMID 36374566); a 2019 mouse pneumonia study tested colistin-glycopeptide combinations against multidrug-resistant Acinetobacter baumannii in animals (PMID 31172805); a 2023 laboratory study reported that chemically modified teicoplanin derivatives blocked spike protein mediated viral entry in SARS-CoV-2 models (PMID 36916436); and a 2022 materials study reported that teicoplanin immobilised onto a surface did not demonstrate antimicrobial activity against Staphylococcus aureus (PMID 36198734). Animal, test tube and surface-coating findings do not establish human indications.

Comparative evidence at a glance

Tolerability and adverse events: What Studies Report

The comparative literature is the main published source on tolerability. In the Cochrane pooled analysis of randomised trials, researchers reported fewer adverse events overall with teicoplanin than with vancomycin, with kidney-related events among the differences noted (PMID 26761092). The 2024 network meta-analysis of six antibiotics in MRSA infection reported safety alongside effectiveness estimates for the agents it compared (PMID 38789000), and the linezolid comparison reported safety outcomes across pooled trials as well (PMID 31626598). Concentration monitoring is discussed in the guideline literature partly in relation to safety as well as efficacy (PMID 35022752). Adverse event profiles in a pooled analysis describe trial populations, not individuals, and a prescribing clinician is the correct source for personal risk assessment.

How to read this evidence sensibly

1. Separate licence from literature. A published trial describing an infection type is not the same as a regulator approving an indication for that infection type.
2. Check which country's label applies. Indication wording, approved routes and population statements differ between national prescribing documents.
3. Treat animal and laboratory work as background. Mouse, test tube and surface-coating studies cited above were explicitly preclinical (PMID 31172805, PMID 36198734).
4. Susceptibility data lead. Reviews of resistant Gram-positive infection stress organism-level testing when choosing among agents (PMID 37067406).

For background on the molecule, its class and its pharmacology, see the overview page at /learn/teicoplanin/.

References

• Cochrane meta-analysis: teicoplanin versus vancomycin for proven or suspected infection (Einstein, 2011)
• Pharmacodynamics of teicoplanin against MRSA (Journal of Antimicrobial Chemotherapy, 2017)
• Efficacy and safety of linezolid versus teicoplanin for the treatment of MRSA infections: a meta-analysis (Journal of Infection in Developing Countries, 2018)
• Colistin-glycopeptide combinations against multidrug-resistant Acinetobacter baumannii in a mouse model of pneumonia (Future Microbiology, 2019)
• Therapeutic Drug Monitoring of Antibiotics: Defining the Therapeutic Range (Therapeutic Drug Monitoring, 2022)
• Clinical practice guidelines for therapeutic drug monitoring of teicoplanin: a consensus review (Journal of Antimicrobial Chemotherapy, 2022)
• Subcutaneously administered antibiotics: a review (Journal of Antimicrobial Chemotherapy, 2022)
• Immobilised teicoplanin does not demonstrate antimicrobial activity against Staphylococcus aureus (Scientific Reports, 2022)
• Therapeutics for Vancomycin-Resistant Enterococcal Bloodstream Infections (Clinical Microbiology Reviews, 2023)
• Teicoplanin derivatives block spike protein mediated viral entry as pan-SARS-CoV-2 inhibitors (Biomedicine & Pharmacotherapy, 2023)
• Dalbavancin as sequential therapy for infective endocarditis due to Gram-positive organisms: a review (International Journal of Antimicrobial Agents, 2023)
• Comparative effectiveness and safety of six antibiotics in treating MRSA infections: A network meta-analysis (International Journal of Infectious Diseases, 2024)